| |
PolyMedix focuses on developing novel high-value therapeutic drug products for serious, life-threatening acute disorders. We attack these challenges with biomimetics - novel small molecule compounds and polymers which mimic the activity of proteins. These compounds are designed with a proprietary computational technology platform which focuses on a specific field of biology with many potential product opportunities: membrane:protein and protein:protein interactions.
PolyMedix focuses on serious, life threatening, acute disorders which are also significant market opportunities. Using our proprietary computational drug design technology, we have created novel antibiotic compounds and heptagonists. Our lead candidates in each of these programs, i.v. antibiotic candidate PMX-30063 and the anticoagulant antagonist product candidate PMX-60056, are
currently in human clinical trials.
PMX-30063 began phase I clinical
trials in August, 2008 and PMX-60056
began clinical trials in September
2008.
PolyMedix is a publicly traded company (OTC BB:PYMX).
June 12, 2009
POLYMEDIX RECEIVES $923,000 SBIR GRANT TO SUPPORT DEVELOPMENT OF LMWH ANTAGONISTS
Grant Represents Eighth Outside Grant or Research Supported Funding
Radnor, PA (June 12, 2009) - PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, has received a Phase II Small Business Innovation Research (SBIR) grant in the amount of $923,080, to be disbursed over two years, to support the development of anticoagulant reversing agents, compounds PolyMedix calls heptagonists.
The sponsoring agency for this grant is the National Institutes of Health (NIH). »read more
|
|
|
June 04, 2009
PolyMedix to Present at Noble Financial Capital Markets 25th Anniversary Fifth Annual Emerging Growth Equity Conference June 8, 2009
Seminole Hotel, Hollywood, Florida, June 8-9, 2009
Radnor, PA (June 4, 2009) - PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, will present at the Noble Financial Capital Markets 25th Anniversary Fifth Annual Emerging Growth Equity Conference. The presentation will take place on Monday June 8 at 2:30 pm E[D]T at the Seminole Hotel, Hollywood, Florida. Nicholas Landekic, PolyMedix’s President & C.E.O., will give a brief corporate overview and an update on the Company's recent developments. »read more
|
|
